Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells
- 25 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 20 (5), 846-858
- https://doi.org/10.1158/1535-7163.mct-20-0476
Abstract
Recent studies have described the remarkable clinical outcome of anti-CD19 chimeric antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of patients develop life-threatening toxicities associated with cytokine release syndrome (CRS) which may limit its utilization in low-resource settings. To mitigate the toxicity, we designed a novel humanized anti-CD19 CAR-T cells by humanizing the framework region of scFv derived from a murine FMC63 mAb and combining it with CD8a transmembrane domain, 4-1BB costimulatory domain and CD3ζ signalling domain (h1CAR19-8BBζ). Docking studies followed by molecular dynamics (MD) simulation revealed that the humanized anti-CD19 scFv (h1CAR19) establishes higher binding affinity and has a flexible molecular structure with CD19 antigen compared to murine scFv (mCAR19). Ex vivo studies with CAR-T cells generated from healthy donors and patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) expressing either h1CAR19 or mCAR19 showed comparable anti-tumor activity and proliferation. More importantly, h1CAR19-8BBζ-T cells produced lower levels of cytokines (IFN-g, TNF-a upon antigen encounter and reduced the induction of IL-6 cytokine from monocytes than mCAR19-8BBζ-T cells. There was a comparable proliferation of h1CAR19-8BBζ-T cells and mCAR19-8BBζ-T cells upon repeated antigen encounter. Finally, h1CAR19-8BBζ-T cells efficiently eliminated NALM6 tumor cells in a preclinical model. In conclusion, the distinct structural modification in CAR design confers the novel humanized anti-CD19 CAR with a favorable balance of efficacy to toxicity providing a rationale to test this construct in a phase I trial.Keywords
Funding Information
- Tata Education and Development Trust (RD/0117TATAE00-001)
- Wadhwani Research Centre for Bioengineering (DO/2017-WRCB002-016)
- Tata Centre at IIT Bombay (DGDON422)
- IIT Bombay (RD/0513-IRCCSH0-021, RD/0115-IRSGHI0-008)
This publication has 47 references indexed in Scilit:
- Early memory phenotypes drive T cell proliferation in patients with pediatric malignanciesScience Translational Medicine, 2016
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivoLeukemia, 2015
- Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICDCancer Immunology Research, 2015
- Design and development of therapies using chimeric antigen receptor‐expressing T cellsImmunological Reviews, 2013
- The HADDOCK web server for data-driven biomolecular dockingNature Protocols, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- VBASE2, an integrative V gene databaseNucleic Acids Research, 2004
- Antibody framework residues affecting the conformation of the hypervariable loopsJournal of Molecular Biology, 1992
- Canonical structures for the hypervariable regions of immunoglobulinsJournal of Molecular Biology, 1987